



ATTENTION

December 2006

EQUALITYCARE PROVIDERS

Pharmacy
Bulletin
06-014

Effective January 2, 2007, Wyoming EqualityCare will cover smoking cessation products for our EqualityCare clients. Clients will be able to receive one course of therapy, as indicated by the respective manufacturer, in a 365 day period. Additional doses or courses of therapy will require authorization by the Office of Pharmacy Services. Products that will be covered are as follows:

- Zyban and its direct generic, bupropion
- Chantix
- Nicotine gum and lozenges
- Nicotine Transdermal Patches

Clients who obtain prescriptions for a smoking cessation product will be followed through the EqualityCare disease case management program administered by APS Healthcare. Clients will also be given information on utilizing the Department of Health's QuitNet and QuitLine.

If you would like to encourage clients to contact the American Cancer Society or the American Heart Association for more information on smoking and how to quit, we encourage you to please do so. This is a wonderful opportunity for pharmacists to counsel their patients on the benefits of quitting smoking, as well as the proper utilization of smoking cessation/nicotine replacement products.

Also effective January 2, 2007, the Wyoming EqualityCare Office of Pharmacy Services will require prior authorization of certain anti-epileptic medications when used for indications other than what the Food and Drug Administration (FDA) has approved. Through the utilization of the SmartPA system, a client's diagnosis history will be checked to verify whether the client has an approved diagnosis for the anti-epileptic prescribed. If the client has a diagnosis that the anti-epileptic has an approved indication for, the claim will pay. If not, the claim will deny, and the prescriber will have to seek approval for the medication through the Office of Pharmacy Services.

The drugs affected by this new policy include the following:
Keppra (Levetiracetam), Lamictal (Lamotrigine), Lyrica (Pregabalin), Neurontin (Gabapentin), Trileptal (Oxcarbazepine), Topamax (Topiramate), and Zoengran (Zonisamide).